Contact
searchSearch
HMP Global
Login

Oncology

Featured

Shannon Westin, MD
Videos
DUO-E Study Suggests Favorable Outcomes with Durvalumab Plus Carboplatin/Paclitaxel Followed by Durvalumab with or without Olaparib in Advanced/Recurrent Endometrial Cancer
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology
FDA Approval
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
11/13/2026
Emily Estrada
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase...
11/13/2026
Oncology
Eleftherios Mamounas, MD, MPH, FACS
Videos
15-Year Follow-Up Data Demonstrates Improved Progression-Free Survival with Extended Letrozole in HR+ Breast Cancer
11/13/2026
Eleftherios Mamounas, MD
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD,...
11/13/2026
Oncology
Nikhil Khushalani, MD
Videos
Global Phase 3 Trial Show Nivolumab Plus HBI-8000 Improved Progression-Free Survival in Advanced Melanoma
11/12/2026
Nikhil Khushalani, MD
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD,...
11/12/2026
Oncology
Jacob Sands, MD
Videos
DeLLphi-305 Trial Shows Tarlatamab Plus Durvalumab Improved Outcomes in Extensive-Stage Small Cell Lung Cancer
11/12/2026
Jacob Sands, MD
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the...
11/12/2026
Oncology
Sara Hurvitz, MD
Videos
TALENT study evaluates T-DXd for HER2-Low, HR-Positive Early-Stage Breast Cancer
11/11/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses...
11/11/2026
Oncology
Benjamin Garmezy, MD
Videos
First-in-Class RIPTAC JNJ-6143 Demonstrates Promising Activity in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer
11/11/2026
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses...
11/11/2026
Oncology
Nilofer Azad, MD
Videos
Tovecimig Plus Paclitaxel Outperforms Paclitaxel Alone in Previously Treated Biliary Tract Cancer
11/11/2026
Nilofer Azad, MD
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses...
11/11/2026
Oncology
Matteo S. Carlino, MD
Videos
Intismeran Plus Pembrolizumab Improves Relapse-Free and Distant Metastasis-Free Survival Resected Stage IIB-IV Melanoma
11/11/2026
Matteo Carlino, MD
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses...
11/11/2026
Oncology
Jaafar Bennouna, MD, PhD
Videos
Adjuvant mFOLFIRINOX Fails to Improve Disease-Free Survival Over mFOLFOX6 in High-Risk Stage III Colon Cancer
11/10/2026
Jaafar Bennouna, MD, PhD
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD,...
11/10/2026
Oncology
FDA Approval
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
11/10/2026
Emily Estrada
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an...
11/10/2026
Oncology

Videos

Shannon Westin, MD
Videos
DUO-E Study Suggests Favorable Outcomes with Durvalumab Plus Carboplatin/Paclitaxel Followed by Durvalumab with or without Olaparib in Advanced/Recurrent Endometrial Cancer
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology
Eleftherios Mamounas, MD, MPH, FACS
Videos
15-Year Follow-Up Data Demonstrates Improved Progression-Free Survival with Extended Letrozole in HR+ Breast Cancer
11/13/2026
Eleftherios Mamounas, MD
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD,...
11/13/2026
Oncology
Nikhil Khushalani, MD
Videos
Global Phase 3 Trial Show Nivolumab Plus HBI-8000 Improved Progression-Free Survival in Advanced Melanoma
11/12/2026
Nikhil Khushalani, MD
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD,...
11/12/2026
Oncology
Jacob Sands, MD
Videos
DeLLphi-305 Trial Shows Tarlatamab Plus Durvalumab Improved Outcomes in Extensive-Stage Small Cell Lung Cancer
11/12/2026
Jacob Sands, MD
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the...
11/12/2026
Oncology
Sara Hurvitz, MD
Videos
TALENT study evaluates T-DXd for HER2-Low, HR-Positive Early-Stage Breast Cancer
11/11/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses...
11/11/2026
Oncology
Benjamin Garmezy, MD
Videos
First-in-Class RIPTAC JNJ-6143 Demonstrates Promising Activity in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer
11/11/2026
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses...
11/11/2026
Oncology
Nilofer Azad, MD
Videos
Tovecimig Plus Paclitaxel Outperforms Paclitaxel Alone in Previously Treated Biliary Tract Cancer
11/11/2026
Nilofer Azad, MD
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses...
11/11/2026
Oncology
Matteo S. Carlino, MD
Videos
Intismeran Plus Pembrolizumab Improves Relapse-Free and Distant Metastasis-Free Survival Resected Stage IIB-IV Melanoma
11/11/2026
Matteo Carlino, MD
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses...
11/11/2026
Oncology
Jaafar Bennouna, MD, PhD
Videos
Adjuvant mFOLFIRINOX Fails to Improve Disease-Free Survival Over mFOLFOX6 in High-Risk Stage III Colon Cancer
11/10/2026
Jaafar Bennouna, MD, PhD
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD,...
11/10/2026
Oncology
Daniel Heng, MD
Videos
Belzutifan Plus Lenvatinib Improves PFS and Response Durability in Advanced Renal Cell Carcinoma
11/09/2026
Daniel Heng, MD
Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...
Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...
Daniel Heng, MD, discusses...
11/09/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Shannon Westin, MD
Videos
DUO-E Study Suggests Favorable Outcomes with Durvalumab Plus Carboplatin/Paclitaxel Followed by Durvalumab with or without Olaparib in Advanced/Recurrent Endometrial Cancer
11/13/2026
Shannon Westin, MD
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center in Houston, discusses findings from the second interim overall survival analysis of the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial, presented at the 2026 ESMO Congress...
Shannon N. Westin, MD, of The...
11/13/2026
Oncology
Eleftherios Mamounas, MD, MPH, FACS
Videos
15-Year Follow-Up Data Demonstrates Improved Progression-Free Survival with Extended Letrozole in HR+ Breast Cancer
11/13/2026
Eleftherios Mamounas, MD
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD, MPH, FACS, discusses the final 15-year analysis of the phase 3 NRG Oncology/NSABP B-42 trial, presented at the 2026 ESMO Congress. The randomized, double-blind, placebo-controlled study evaluated whether 5...
Eleftherios P. Mamounas, MD,...
11/13/2026
Oncology
Nikhil Khushalani, MD
Videos
Global Phase 3 Trial Show Nivolumab Plus HBI-8000 Improved Progression-Free Survival in Advanced Melanoma
11/12/2026
Nikhil Khushalani, MD
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD, discusses the primary analysis of the phase 3 HBI-8000-303 trial, presented at the 2026 ESMO Congress in Madrid, Spain. The global, randomized study evaluated HBI-8000, an oral selective histone deacetylase (HDAC)...
Nikhil I. Khushalani, MD,...
11/12/2026
Oncology
Jacob Sands, MD
Videos
DeLLphi-305 Trial Shows Tarlatamab Plus Durvalumab Improved Outcomes in Extensive-Stage Small Cell Lung Cancer
11/12/2026
Jacob Sands, MD
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the primary analysis of the phase 3 DeLLphi-305 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Jacob Sands, MD, discusses the...
11/12/2026
Oncology
Sara Hurvitz, MD
Videos
TALENT study evaluates T-DXd for HER2-Low, HR-Positive Early-Stage Breast Cancer
11/11/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses final results from TALENT, a phase 2 investigator-initiated neoadjuvant trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
Sara Hurvitz, MD, discusses...
11/11/2026
Oncology
Benjamin Garmezy, MD
Videos
First-in-Class RIPTAC JNJ-6143 Demonstrates Promising Activity in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer
11/11/2026
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses phase 1 results evaluating the first-in-class androgen receptor–targeted RIPTAC JNJ-6143 in heavily pretreated metastatic castration-resistant prostate cancer, highlighting encouraging PSA responses across...
Benjamin Garmazy, MD, discusses...
11/11/2026
Oncology
Nilofer Azad, MD
Videos
Tovecimig Plus Paclitaxel Outperforms Paclitaxel Alone in Previously Treated Biliary Tract Cancer
11/11/2026
Nilofer Azad, MD
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses results from a randomized phase 3 trial evaluating tovecimig plus paclitaxel versus paclitaxel alone in previously treated advanced biliary tract cancer, highlighting improved response rates and progression-free...
Nilofer Azad, MD, discusses...
11/11/2026
Oncology
Matteo S. Carlino, MD
Videos
Intismeran Plus Pembrolizumab Improves Relapse-Free and Distant Metastasis-Free Survival Resected Stage IIB-IV Melanoma
11/11/2026
Matteo Carlino, MD
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses results from the phase 3 INTerpath-001 trial evaluating personalized neoantigen therapy with intismeran autogene plus pembrolizumab in resected melanoma, highlighting improved recurrence-free and distant...
Matteo Carlino, MD, discusses...
11/11/2026
Oncology
Jaafar Bennouna, MD, PhD
Videos
Adjuvant mFOLFIRINOX Fails to Improve Disease-Free Survival Over mFOLFOX6 in High-Risk Stage III Colon Cancer
11/10/2026
Jaafar Bennouna, MD, PhD
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD, discusses results from the phase 3 IROCAS trial comparing adjuvant mFOLFIRINOX with mFOLFOX6 in patients with resected high-risk stage III colon cancer, highlighting the absence of disease-free survival improvement,...
Jaafar Bennouna, MD, PhD,...
11/10/2026
Oncology
Daniel Heng, MD
Videos
Belzutifan Plus Lenvatinib Improves PFS and Response Durability in Advanced Renal Cell Carcinoma
11/09/2026
Daniel Heng, MD
Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...
Daniel Heng, MD, discusses updated results from the LITESPARK-011 trial evaluating belzutifan plus lenvatinib versus cabozantinib in advanced renal cell carcinoma, highlighting improved progression-free survival, higher response rates,...
Daniel Heng, MD, discusses...
11/09/2026
Oncology

Live Meetings

Recent News

FDA Approval
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
11/13/2026
Emily Estrada
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase...
11/13/2026
Oncology
FDA Approval
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
11/10/2026
Emily Estrada
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may cause worsening functional limitations or severe morbidity, based on the results from the phase 3 MANEUVER...
The FDA approved pimicotinib, an...
11/10/2026
Oncology
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use